biostudies-literatureOtt PANCI NIH HHSe8714https://www.ebi.ac.uk/biostudies/studies/S-EPMC2808339biostudies-literatureUnknown5(1)<h4>Background</h4>Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was investigated in two different cohorts: chemotherapy-naïve (previously untreated) and previously treated patients with metastatic melanoma.<h4>Methodology/principal findings</h4>Eligible patients had histologically-confirmed stage IV melanoma, with an ECOG performance status of 0 to 2. Ixabepilone was administered at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle. The primary endpoint was response rate (RR); secondary endpoints were time to progression (TTP) and toxicity. TwPloS oneA phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.PMC2808339N01 CM062204N01-CM-62204U01 CA0766421U01 CA76642Doyle LAMillward MOtt PAPavlick ACHaas NLiddell SHamilton AJones AChristos PJShore TMuggia FMfalseA phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.<h4>Background</h4>Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was investigated in two different cohorts: chemotherapy-naïve (previously untreated) and previously treated patients with metastatic melanoma.<h4>Methodology/principal findings</h4>Eligible patients had histologically-confirmed stage IV melanoma, with an ECOG performance status of 0 to 2. Ixabepilone was administered at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle. The primary endpoint was response rate (RR); secondary endpoints were time to progression (TTP) and toxicity. Tw2010-01-01T00:00:00Z2010 Jan2026-04-30T22:20:46.903Z2026-04-07T16:22:54.92ZS-EPMC28083392009869410.1371/journal.pone.0008714